Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017, Article ID 7065759, 9 pages
https://doi.org/10.1155/2017/7065759
Case Report

Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion

1University of Texas Southwestern Medical Center, Dallas, TX, USA
2Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

Correspondence should be addressed to Candace Wu; ude.nretsewhtuostu@uw.ecadnac

Received 1 November 2016; Accepted 13 April 2017; Published 27 April 2017

Academic Editor: Kuan-Rau Chiou

Copyright © 2017 Candace Wu and Kamal Shemisa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Valsuani, O. Siclari, A. Camerini et al., “Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report,” Cases Journal, vol. 2, no. 12, article no. 9133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. S. Hall, L. C. Harshman, S. Srinivas, and R. M. Witteles, “The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients,” JACC: Heart Failure, vol. 1, no. 1, pp. 72–78, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Condorelli, A. Drusco, G. Stassi et al., “Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12333–12338, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Yamazaki, I. Komuro, and Y. Yazaki, “Signalling pathways for cardiac hypertrophy,” Cellular Signalling, vol. 10, no. 10, pp. 693–698, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Cobleigh, C. L. Vogel, D. Tripathy et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2639–2648, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Rossi, G. Carioli, M. Bonifazi et al., “Trastuzumab for HER2+ metastatic breast cancer in clinical practice: cardiotoxicity and overall survival,” European Journal of Cancer, vol. 52, pp. 41–49, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Bonifazi, M. Franchi, M. Rossi et al., “Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study,” Oncologist, vol. 18, no. 7, pp. 795–801, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Procter, T. M. Suter, E. de Azambuja et al., “Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial,” Journal of Clinical Oncology, vol. 28, no. 21, pp. 3422–3428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Pivot, T. Suter, J. M. Nabholtz et al., “Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study,” European Journal of Cancer, vol. 51, no. 13, article 9505, pp. 1660–1666, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. E. De Azambuja, M. J. Procter, D. J. Van Veldhuisen et al., “Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01),” Journal of Clinical Oncology, vol. 32, no. 20, pp. 2159–2165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Force, D. S. Krause, and R. A. Van Etten, “Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition,” Nature Reviews Cancer, vol. 7, no. 5, pp. 332–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. O. F. Bueno, L. J. De Windt, K. M. Tymitz et al., “The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice,” The European Molecular Biology Organization Journal, vol. 19, pp. 6341–6350, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. B. B. Hasinoff, D. Patel, and X. Wu, “The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin,” Cardiovascular Toxicology, vol. 13, no. 1, pp. 33–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Yamaguchi, T. Watanabe, K. Nishida et al., “Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis,” The Journal of Clinical Investigation, vol. 114, no. 7, pp. 937–943, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. I. S. Harris, S. Zhang, I. Treskov, A. Kovacs, C. Weinheimer, and A. J. Muslin, “Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload,” Circulation, vol. 110, no. 6, pp. 718–723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Park, S.-H. Han, H. Kang, and K. Park, “A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma,” International Journal of Cardiology, vol. 160, no. 1, pp. e10–e11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Rohrbach, X. Yan, E. O. Weinberg et al., “Neuregulin in cardiac hypertrophy in rats with aortic stenosis: differential expression of erbB2 and erbB4 receptors,” Circulation, vol. 100, no. 4, pp. 407–412, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. A. M. J. Thijs, C. M. L. Van Herpen, F. C. G. J. Sweep et al., “Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans,” Hypertension, vol. 61, no. 5, pp. 1060–1065, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-J. Mourad, G. des Guetz, H. Debbabi, and B. I. Levy, “Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation,” Annals of Oncology, vol. 19, no. 5, pp. 927–934, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. W.-X. Qi, S. Fu, Q. Zhang, and X.-M. Guo, “Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups,” Clinical Drug Investigation, vol. 34, no. 10, pp. 681–690, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. P. Escalante, Y. C. Chang, K. Liao et al., “Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents,” Supportive Care in Cancer, vol. 24, no. 9, pp. 4057–4074, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Ghatalia, C. J. Morgan, Y. Je et al., “Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors,” Critical Reviews in Oncology/Hematology, vol. 94, no. 2, pp. 228–237, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Szmit, P. Langiewicz, J. Zlnierek, P. Nurzynski, M. Zaborowska, K. J. Filipiak et al., “Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.,” in Kidney And Blood Pressure Research, vol. 35, pp. 18–25, 2012. View at Google Scholar
  25. D. J. Lenihan and P. R. Kowey, “Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors,” Oncologist, vol. 18, no. 8, pp. 900–908, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Ky, P. Vejpongsa, E. T. H. Yeh, T. Force, and J. J. Moslehi, “Emerging paradigms in cardiomyopathies associated with cancer therapies,” Circulation Research, vol. 113, no. 6, pp. 754–764, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. W. C. Yancy, M. Jessup, B. Bozkurt et al., “Guideline for the management of heart failure,” Circulation, vol. 128, pp. e240–e327, 2013. View at Publisher · View at Google Scholar
  28. R. C. Hendel, M. R. Patel, C. M. Kramer, M. Poon, J. C. Carr, N. A. Gerstad et al., “ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology,” Journal of the American College of Cardiology, vol. 48, pp. 1475–1497, 2006. View at Google Scholar
  29. Y.-L. Chen, S.-Y. Chung, H.-T. Chai et al., “Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy,” Journal of Pharmacology and Experimental Therapeutics, vol. 355, no. 3, pp. 516–527, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Janbabai, M. Nabati, M. Faghihinia, S. Azizi, S. Borhani, and J. Yazdani, “Effect of enalapril on preventing anthracycline-induced cardiomyopathy,” Cardiovascular Toxicology, pp. 1–10, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. L. C. Hool, L. M. Middleton, and R. D. Harvey, “Genistein increases the sensitivity of cardiac ion channels to β-adrenergic receptor stimulation,” Circulation Research, vol. 83, no. 1, pp. 33–42, 1998. View at Publisher · View at Google Scholar · View at Scopus